A Study of Insulin Lispro With BioChaperone Excipient in Healthy Participants
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
BC106 is a molecule that when injected with insulin lispro may change the speed of absorption
of insulin lispro. The purpose of this study will be to evaluate the safety of BC106 insulin
lispro and any side effects that might be associated with it, blood levels of insulin lispro
after injection under the skin and how BC106 insulin lispro affects blood sugar after
injection under the skin. There is a minimum 7 day washout between single doses.